Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have earned an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $8.00.

CGTX has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Cognition Therapeutics in a report on Wednesday, November 27th. Chardan Capital reiterated a “buy” rating and issued a $11.00 target price on shares of Cognition Therapeutics in a report on Friday, November 15th. Finally, B. Riley reiterated a “neutral” rating and issued a $1.00 target price (down previously from $5.00) on shares of Cognition Therapeutics in a report on Tuesday, August 6th.

Cognition Therapeutics Trading Down 3.3 %

Shares of Cognition Therapeutics stock opened at $0.39 on Friday. The company’s 50-day moving average price is $0.46 and its two-hundred day moving average price is $1.07. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The stock has a market cap of $16.08 million, a PE ratio of -0.40 and a beta of 1.26.

Institutional Investors Weigh In On Cognition Therapeutics

Several large investors have recently made changes to their positions in CGTX. Bangor Savings Bank grew its stake in shares of Cognition Therapeutics by 41.6% in the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares in the last quarter. CM Management LLC boosted its position in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after purchasing an additional 25,000 shares during the period. Mercer Global Advisors Inc. ADV boosted its position in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the period. Sigma Planning Corp boosted its position in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the period. Finally, Virtu Financial LLC bought a new stake in Cognition Therapeutics during the third quarter worth approximately $27,000. Institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.